Resource Centre

A Phase 1, Randomized, Double-Blind, PlaceboControlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers

The purpose of this study is to analyze pharmaceutical and clinical data from multiple development programs to understand the drivers and outcomes of selecting and dosing different lipid formulations.

A Quotient Sciences Poster by Erika Reategui, Director, GCP Quality Assurance, Quality Assurance: Why Archiving is a Crucial Part of Any Clinical Trial

Quotient Sciences Poster : An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects

Quotient Sciences' Poster: Influence of drug loading and fillers on drug release from HPMC matrix tablets

Quotient Sciences Poster: Development of modified release matrix tablet formulation using solid lipid Compritol 888 for a poorly water soluble drug

Quotient Sciences EBF 2021 Poster: Analysis of Ranitidine Reference Materials Using a Six N-Nitrosamine LC-MS/MS Assay

Download our poster from the EBF 2021 conference entitled: Novel Copper Protein Speciation Method for Calculating Serum Non Ceruloplasmin Copper: A Comparative Analysis

Download our poster from the EBF 2021 conference entitled: Analysis of Ranitidine Reference Materials Using a Six N-Nitrosamine LC-MS/MS Assay

Access our latest poster from AAPS 2021- Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations. The purpose of this study is to review practical experiences of head to head pharmaceutical and clinical comparisons of MUPs and matrix tablet platforms to identify an optimal MR formulation.

Download our AAPS 2021 poster entitled: Development and Application of a PBPK Model Using Theoretical Particle Size Distribution to Describe in vivo D issolution to Predict the Impact of Formulation Changes on Oral Bioavailability of GB001

Presented at the annual EuPFI event, this poster documents the project of Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders.